Targeting PD-1 in Rheumatoid Arthritis The results of the large Phase 2b RENOIR trial showed that rosnilimab, a monoclonal antibody targeting PD-1, was effective in moderate-to-severe rheumatoid arthritis (RA) patients. https://t.co/ZsS3JOqdLh https://t.co/3JByNrLTGR